Skip to main content

Table 2 Characteristics (demographics and comorbidity) at the start of therapy with generic or brand-name statin

From: Treatment persistence and adherence and their consequences on patient outcomes of generic versus brand-name statins routinely used to treat high cholesterol levels in Spain: a retrospective cost-consequences analysis

Group Brand-name Generic Total p
Number of patients (%) 3007 (22.7%) 10,237 (77.3%) 13,244 (100%)
Sociodemographic characteristics
Average age (years) 61.4 (11.7) 61.2 (11.3) 61.3 (11.4) 0.501
Ranges:     
 18–44 years 7.2% 7.7% 7.6%  
 45–64 years 52.9% 51.9% 52.1%  
 65–74 years 23.0% 25.9% 25.2%  
  ≥ 75 years 16.8% 14.6% 15.1% 0.234
Sex (female) 52.7% 52.5% 52.6% 0.827
Pensioners 50.2% 51.6% 50.5% 0.191
General comorbidity
 Average diagnoses 6.6 (3.6) 6.5 (3.3) 6.5 (3.3) 0.502
 Charlson index 0.7 (1.0) 0.7 (1.0) 0.7 (1.0) 0.855
 Average RUB 2.9 (0.7) 3.0 (0.7) 3.0 (0.7) 0.527
 1 (very low comorbidity) 3.9% 3.4% 3.5%  
 2 (low comorbidity) 15.4% 14.8% 14.9%  
 3 (moderate comorbidity) 65.5% 66.7% 66.4%  
 4 (high comorbidity) 13.2% 13.2% 13.2%  
 5 (very high comorbidity) 2.1% 1.9% 1.9%  
Associated comorbidities
 Hypertension 50.2% 51.6% 50.5% 0.191
 Diabetes mellitus 22.8% 23.0% 22.9% 0.786
 Obesity 19.4% 19.8% 19.5% 0.658
 Active smokers 24.0% 22.9% 23.7% 0.224
 Alcoholism 3.5% 4.2% 3.7% 0.064
 Ischemic heart disease 8.3% 9.4% 8.5% 0.057
 Cerebrovascular accident 11.0% 9.9% 10.8% 0.091
 Previous cardiovascular event 19.0% 18.3% 18.8% 0.382
 Organ failure 17.3% 17.7% 17.4% 0.675
 Dementia 2.4% 2.5% 2.5% 0.792
 Depressive syndrome 21.5% 21.4% 21.5% 0.182
 Malignant neoplasms 9.4% 9.0% 9.3% 0.537
  1. Values expressed as percentage or mean (standard deviation), p statistical significance between brand-name vs. generic, RUB resource utilization band